全体要約
抗体薬物複合体受託製造市場は、2023年に2827.3百万米ドルと推定され、2030年には9332.5百万米ドルに達する見込みで、2024年から2030年の間に年平均成長率（CAGR）は18.9%と予測されています。
主要企業にはLonza、Merck、Recipharmがあり、これらの企業は市場の約50%を占めています。北米は市場シェアの約35%を占め、IgG1が主要な製品タイプです。
市場の半分以上は固形腫瘍の適用に関連しており、抗体薬物複合体は化学結合を通じてモノクローナル抗体と結びつき、標的細胞に対して細胞毒性薬を運ぶ役割を果たします。最初の抗体薬物複合体は2000年にFDAに承認されたMylotarg®で、これにより抗体薬物複合体を用いたがん治療の時代が始まりました。
関連する質問
2827.3百万米ドル（2023年）
18.9%（2024年-2030年）
Lonza, Merck, Recipharm, Thermo Fisher, AbbVie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions, Curia, Novasep, Ajinomoto Bio-Pharma Services, BSP Pharmaceuticals, Cerbios-Pharma, Goodwin Biotechnology
モノクローナル抗体のターゲティング能力, 固形腫瘍治療の需要増加, 高度な製造技術の進展
概要
抗体薬物複合体受託製造の世界市場は、2023年に28億2730万米ドルの価値があると推定され、2030年までに93億3250万米ドルに再調整される予測です。予測期間2024年から2030年の間に年平均成長率（CAGR）は18.9％です。
抗体薬物複合体（ADC）受託製造の主要なグローバル企業には、ロンザ、メルク、レシファーム、サーモフィッシャー、アッヴィ、ピラマルファーマソリューションズ、カタレント、スターリングファーマソリューションズ、キュリアがあります。トップ3のプレーヤーはロンザ、メルク、レシファームで、彼らは合わせて世界市場シェアの約50%を占めています。最大のプレーヤーはロンザグループです。生産面では、世界のプレーヤーは主に北米とヨーロッパに集中しています。北米は世界市場シェアの約35%を占めています。タイプ別では、IgG1が世界の抗体薬物複合体受託製造市場で優勢です。アプリケーション別では、固形腫瘍のアプリケーションが市場の半分以上を占めています。
レポートの範囲
本レポートは、抗体薬物複合体契約製造のグローバル市場について、定量的および定性的な分析を提供し、読者がビジネスや成長戦略を策定し、市場の競争状況を評価し、現在の市場における自社の位置を分析し、抗体薬物複合体契約製造に関する情報に基づいたビジネス判断を行うのを助けることを目的としています。
抗体薬物複合体契約製造市場の規模、推定値、予測は、2023年を基準年とし、2019年から2030年までの期間に関する歴史的データと予測データに基づいて、収益（百万ドル）で提供されます。この報告書は、グローバルな抗体薬物複合体契約製造市場を包括的にセグメント化しています。製品タイプ、用途、プレーヤーによる地域市場の規模も提供されています。
市場をより深く理解するために、レポートは競争環境のプロファイル、主要競合他社、およびそれぞれの市場ランクを提供。また、技術トレンドや新製品の開発についても議論しています。
このレポートは、抗体薬物複合体契約製造企業、新規参入者、およびこの市場に関連する業界チェーン企業に対して、企業、製品タイプ、アプリケーション、地域別の全体市場およびサブセグメントの収益に関する情報を提供します。
市場セグメンテーション
会社別
ロンザグループ
メルクKGaA
レシファーム
サーモフィッシャーサイエンティフィック
アッヴィ
ピラマルファーマソリューションズ
カタレント
スターリング・ファーマ・ソリューションズ
キュリア
Novasep
味の素バイオファーマサービス
BSP製薬
セルビオス・ファーマ
グッドウィンバイオテクノロジー
タイプ別セグメント
IgG1
IgG4
アプリケーション別セグメント
固形腫瘍
血液悪性腫瘍
地域別
北アメリカ
アメリカ合衆国
カナダ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
北欧諸国
その他のヨーロッパ
アジア太平洋
中国
日本
韓国
インド
東南アジア
オーストラリア
アジア太平洋地域のその他
ラテンアメリカ
メキシコ
ブラジル
中南米の残り
中東およびアフリカ
トルコ
サウジアラビア
UAE（アラブ首長国連邦）
中東およびアフリカの残りの部分
章の概要
第1章：報告書の範囲、異なる市場セグメント（製品タイプ、用途など）のエグゼクティブサマリーを紹介し、各市場セグメントの市場規模、今後の発展可能性などを含みます。
第2章：抗体薬物複合体の受託製造における収益（グローバルおよび地域レベル）
第3章：抗体薬物複合体の受託製造企業の競争環境、収益、市場シェアおよび業界ランキング、最新の開発計画、合併および買収情報などの詳細分析。
第4章：主要企業のプロファイルを提供し、市場の主要企業の基本状況を詳細に紹介します。これには、製品の説明や仕様、抗体薬物共役体の契約製造収益、粗利益、最近の開発などが含まれます。
第5章：各市場セグメントの種類による分析を提供し、各市場セグメントの収益と発展の可能性をカバーします。これにより読者は異なる市場セグメントにおけるブルーオーシャン市場を見つけることができます。
第6章：アプリケーション別のさまざまな市場セグメントの分析を提供し、各市場セグメントの収益と発展の可能性をカバーし、読者が異なる下流市場でブルーオーシャン市場を見つけるのを助けます。
第7章：北アメリカ（米国およびカナダ）種類別、用途別、国別、各セグメントの収益。
第8章：タイプ別、用途別および国別のヨーロッパ、各セグメントの収益。
第9章：アジア太平洋地域のタイプ別、アプリケーション別、地域別、各セグメントの収益。
第10章：ラテンアメリカのタイプ別、アプリケーション別および国別、各セグメントの収益。
第11章：中東およびアフリカ、タイプ別、アプリケーション別および国別、各セグメントの収益。
第12章：産業チェーン、販売チャネル、主要原材料、流通業者、および顧客の分析。
第13章では、市場の動態、市場の最新の発展、市場の推進要因および制約要因、業界の製造業者が直面する課題とリスク、業界における関連政策の分析を紹介します。
第14章：研究結果と結論
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 調査のカバー範囲
1.1 抗体薬物複合体受託製造 : プロダクトのイントロダクション
1.2 市場、タイプ別
1.2.1 グローバルにおける抗体薬物複合体受託製造市場規模成長率、タイプ別（2019年 vs 2023年 vs 2030年）
1.2.2 IgG1
1.2.3 IgG4
1.3 市場、用途別
1.3.1 グローバルにおける抗体薬物複合体受託製造市場規模成長率、用途別（2019年 vs 2023年 vs 2030年）
1.3.2 固形腫瘍
1.3.3 血液悪性腫瘍
1.4 前提条件と限界
1.5 調査の目的
1.6 対象年
2 エグゼクティブサマリー
2.1 グローバルにおける抗体薬物複合体受託製造市場規模の見積もりと予測
2.2 抗体薬物複合体受託製造市場規模、地域別：2023年と2030年の比較
2.2.1 グローバルにおける抗体薬物複合体受託製造市場の収益規模、地域別 2019年～2024年
2.2.2 グローバルの抗体薬物複合体受託製造収益、市場予測（地域別）（2025年～2030年）
2.2.3 グローバルにおける抗体薬物複合体受託製造市場の収益シェア、地域別（2019年～2030年）
3 グローバルにおける抗体薬物複合体受託製造、企業別
3.1 グローバルにおける抗体薬物複合体受託製造市場の収益規模、企業別（2019年～2024年）
3.2 グローバルにおける抗体薬物複合体受託製造市場の収益シェア、企業別（2019年〜2024年）
3.3 競合情勢
3.3.1 Key Antibody Drug Conjugates Contract Manufacturing Companies around the World: Ranking by Revenue
3.3.2 Global Antibody Drug Conjugates Contract Manufacturing Market Concentration Ratio \(CR5 and HHI\) & \(2019-2024\)
3.3.3 Global Antibody Drug Conjugates Contract Manufacturing Market Share by Company Type \(Tier 1, Tier 2 and Tier 3\)
3.4 グローバルにおける抗体薬物複合体受託製造の会社所在地と製品タイプ
3.4.1 抗体薬物複合体受託製造の会社所在地
3.4.2 グローバルにおける抗体薬物複合体受託製造の製品・サービス
3.4.3 国際企業の抗体薬物複合体受託製造市場への参入日
3.5 グローバルにおける抗体薬物複合体受託製造のM&A、事業拡張計画
4 企業プロファイル
4.1 Lonza Group
4.1.1 Lonza Group：企業情報
4.1.2 Lonza Group：会社概要、事業概要
4.1.3 Lonza Group：抗体薬物複合体受託製造の製品
4.1.4 Lonza Group：抗体薬物複合体受託製造の収益および売上総利益率（2019年〜2024年）
4.1.5 Lonza Group：製品別の抗体薬物複合体受託製造の収益（2023年）
4.1.6 Lonza Group：用途別の抗体薬物複合体受託製造の収益（2023年）
4.1.7 Lonza Group：地理別の抗体薬物複合体受託製造の収益（2023年）
4.1.8 Lonza Group：近況
4.2 Merck KGaA
4.2.1 Merck KGaA：企業情報
4.2.2 Merck KGaA：会社概要、事業概要
4.2.3 Merck KGaA：抗体薬物複合体受託製造の製品
4.2.4 Merck KGaA：抗体薬物複合体受託製造の収益および売上総利益率（2019年〜2024年）
4.2.5 Merck KGaA：製品別の抗体薬物複合体受託製造の収益（2023年）
4.2.6 Merck KGaA：用途別の抗体薬物複合体受託製造の収益（2023年）
4.2.7 Merck KGaA：地理別の抗体薬物複合体受託製造の収益（2023年）
4.2.8 Merck KGaA：近況
4.3 Recipharm
4.3.1 Recipharm：企業情報
4.3.2 Recipharm：会社概要、事業概要
4.3.3 Recipharm：抗体薬物複合体受託製造の製品
4.3.4 Recipharm：抗体薬物複合体受託製造の収益および売上総利益率（2019年〜2024年）
4.3.5 Recipharm：製品別の抗体薬物複合体受託製造の収益（2023年）
4.3.6 Recipharm：用途別の抗体薬物複合体受託製造の収益（2023年）
4.3.7 Recipharm：地理別の抗体薬物複合体受託製造の収益（2023年）
4.3.8 Recipharm：近況
4.4 Thermo Fisher Scientific
4.4.1 Thermo Fisher Scientific：企業情報
4.4.2 Thermo Fisher Scientific：会社概要、事業概要
4.4.3 Thermo Fisher Scientific：抗体薬物複合体受託製造の製品
4.4.4 Thermo Fisher Scientific：抗体薬物複合体受託製造の収益および売上総利益率（2019年〜2024年）
4.4.5 Thermo Fisher Scientific：製品別の抗体薬物複合体受託製造の収益（2023年）
4.4.6 Thermo Fisher Scientific：用途別の抗体薬物複合体受託製造の収益（2023年）
4.4.7 Thermo Fisher Scientific：地理別の抗体薬物複合体受託製造の収益（2023年）
4.4.8 Thermo Fisher Scientific：近況
4.5 Abbvie
4.5.1 Abbvie：企業情報
4.5.2 Abbvie：会社概要、事業概要
4.5.3 Abbvie：抗体薬物複合体受託製造の製品
4.5.4 Abbvie：抗体薬物複合体受託製造の収益および売上総利益率（2019年〜2024年）
4.5.5 Abbvie：製品別の抗体薬物複合体受託製造の収益（2023年）
4.5.6 Abbvie：用途別の抗体薬物複合体受託製造の収益（2023年）
4.5.7 Abbvie：地理別の抗体薬物複合体受託製造の収益（2023年）
4.5.8 Abbvie：近況
4.6 Piramal Pharma Solutions
4.6.1 Piramal Pharma Solutions：企業情報
4.6.2 Piramal Pharma Solutions：会社概要、事業概要
4.6.3 Piramal Pharma Solutions：抗体薬物複合体受託製造の製品
4.6.4 Piramal Pharma Solutions：抗体薬物複合体受託製造の収益および売上総利益率（2019年〜2024年）
4.6.5 Piramal Pharma Solutions：製品別の抗体薬物複合体受託製造の収益（2023年）
4.6.6 Piramal Pharma Solutions：用途別の抗体薬物複合体受託製造の収益（2023年）
4.6.7 Piramal Pharma Solutions：地理別の抗体薬物複合体受託製造の収益（2023年）
4.6.8 Piramal Pharma Solutions直近の動向
4.7 Catalent
4.7.1 Catalent：企業情報
4.7.2 Catalent：会社概要、事業概要
4.7.3 Catalent：抗体薬物複合体受託製造の製品
4.7.4 Catalent：抗体薬物複合体受託製造の収益および売上総利益率（2019年〜2024年）
4.7.5 Catalent：製品別の抗体薬物複合体受託製造の収益（2023年）
4.7.6 Catalent：用途別の抗体薬物複合体受託製造の収益（2023年）
4.7.7 Catalent：地理別の抗体薬物複合体受託製造の収益（2023年）
4.7.8 Catalent直近の動向
4.8 Sterling Pharma Solutions
4.8.1 Sterling Pharma Solutions：企業情報
4.8.2 Sterling Pharma Solutions：会社概要、事業概要
4.8.3 Sterling Pharma Solutions：抗体薬物複合体受託製造の製品
4.8.4 Sterling Pharma Solutions：抗体薬物複合体受託製造の収益および売上総利益率（2019年〜2024年）
4.8.5 Sterling Pharma Solutions：製品別の抗体薬物複合体受託製造の収益（2023年）
4.8.6 Sterling Pharma Solutions：用途別の抗体薬物複合体受託製造の収益（2023年）
4.8.7 Sterling Pharma Solutions：地理別の抗体薬物複合体受託製造の収益（2023年）
4.8.8 Sterling Pharma Solutions直近の動向
4.9 Curia
4.9.1 Curia：企業情報
4.9.2 Curia：会社概要、事業概要
4.9.3 Curia：抗体薬物複合体受託製造の製品
4.9.4 Curia：抗体薬物複合体受託製造の収益および売上総利益率（2019年〜2024年）
4.9.5 Curia：製品別の抗体薬物複合体受託製造の収益（2023年）
4.9.6 Curia：用途別の抗体薬物複合体受託製造の収益（2023年）
4.9.7 Curia：地理別の抗体薬物複合体受託製造の収益（2023年）
4.9.8 Curia直近の動向
4.10 Novasep
4.10.1 Novasep：企業情報
4.10.2 Novasep：会社概要、事業概要
4.10.3 Novasep：抗体薬物複合体受託製造の製品
4.10.4 Novasep：抗体薬物複合体受託製造の収益および売上総利益率（2019年〜2024年）
4.10.5 Novasep：製品別の抗体薬物複合体受託製造の収益（2023年）
4.10.6 Novasep：用途別の抗体薬物複合体受託製造の収益（2023年）
4.10.7 Novasep：地理別の抗体薬物複合体受託製造の収益（2023年）
4.10.8 Novasep直近の動向
4.11 Ajinomoto Bio-Pharma Services
4.11.1 Ajinomoto Bio-Pharma Services：企業情報
4.11.2 Ajinomoto Bio-Pharma Services：会社概要、事業概要
4.11.3 Ajinomoto Bio-Pharma Services：抗体薬物複合体受託製造の製品
4.11.4 Ajinomoto Bio-Pharma Services：抗体薬物複合体受託製造の収益および売上総利益率（2019年〜2024年）
4.11.5 Ajinomoto Bio-Pharma Services：製品別の抗体薬物複合体受託製造の収益（2023年）
4.11.6 Ajinomoto Bio-Pharma Services：用途別の抗体薬物複合体受託製造の収益（2023年）
4.11.7 Ajinomoto Bio-Pharma Services：地理別の抗体薬物複合体受託製造の収益（2023年）
4.11.8 Ajinomoto Bio-Pharma Services直近の動向
4.12 BSP Pharmaceuticals
4.12.1 BSP Pharmaceuticals：企業情報
4.12.2 BSP Pharmaceuticals：会社概要、事業概要
4.12.3 BSP Pharmaceuticals：抗体薬物複合体受託製造の製品
4.12.4 BSP Pharmaceuticals：抗体薬物複合体受託製造の収益および売上総利益率（2019年〜2024年）
4.12.5 BSP Pharmaceuticals：製品別の抗体薬物複合体受託製造の収益（2023年）
4.12.6 BSP Pharmaceuticals：用途別の抗体薬物複合体受託製造の収益（2023年）
4.12.7 BSP Pharmaceuticals：地理別の抗体薬物複合体受託製造の収益（2023年）
4.12.8 BSP Pharmaceuticals直近の動向
4.13 Cerbios-Pharma
4.13.1 Cerbios-Pharma：企業情報
4.13.2 Cerbios-Pharma：会社概要、事業概要
4.13.3 Cerbios-Pharma：抗体薬物複合体受託製造の製品
4.13.4 Cerbios-Pharma：抗体薬物複合体受託製造の収益および売上総利益率（2019年〜2024年）
4.13.5 Cerbios-Pharma：製品別の抗体薬物複合体受託製造の収益（2023年）
4.13.6 Cerbios-Pharma：用途別の抗体薬物複合体受託製造の収益（2023年）
4.13.7 Cerbios-Pharma：地理別の抗体薬物複合体受託製造の収益（2023年）
4.13.8 Cerbios-Pharma直近の動向
4.14 Goodwin Biotechnology
4.14.1 Goodwin Biotechnology：企業情報
4.14.2 Goodwin Biotechnology：会社概要、事業概要
4.14.3 Goodwin Biotechnology：抗体薬物複合体受託製造の製品
4.14.4 Goodwin Biotechnology：抗体薬物複合体受託製造の収益および売上総利益率（2019年〜2024年）
4.14.5 Goodwin Biotechnology：製品別の抗体薬物複合体受託製造の収益（2023年）
4.14.6 Goodwin Biotechnology：用途別の抗体薬物複合体受託製造の収益（2023年）
4.14.7 Goodwin Biotechnology：地理別の抗体薬物複合体受託製造の収益（2023年）
4.14.8 Goodwin Biotechnology直近の動向
5 ブレークダウンデータ、タイプ別
5.1 グローバルにおける抗体薬物複合体受託製造市場の収益規模、タイプ別（2019年～2024年）
5.2 グローバルの抗体薬物複合体受託製造収益、市場予測（タイプ別）（2025年～2030年）
5.3 抗体薬物複合体受託製造の収益と市場シェア、タイプ別（2019年〜2030年）
6 ブレークダウンデータ、用途別
6.1 グローバルにおける抗体薬物複合体受託製造市場の収益規模、用途別（2019年～2024年）
6.2 グローバルの抗体薬物複合体受託製造収益、市場予測（用途別）（2025年～2030年）
6.3 抗体薬物複合体受託製造の収益と市場シェア、用途別（2019年〜2030年）
7 北米
7.1 北米における抗体薬物複合体受託製造市場規模の前年比成長率、2019年〜2030年
7.2 北米における抗体薬物複合体受託製造市場のファクト・数値、 国別（2019年〜2030年）
7.3 北米における抗体薬物複合体受託製造市場の収益規模、タイプ別（2019年～2024年）
7.4 北米における抗体薬物複合体受託製造市場の収益規模、用途別（2019年～2024年）
8 アジア太平洋
8.1 アジア太平洋における抗体薬物複合体受託製造市場規模の前年比成長率、2019年〜2030年
8.2 アジア太平洋における抗体薬物複合体受託製造市場のファクト・数値、 地域別（2019年〜2030年）
8.3 アジア太平洋における抗体薬物複合体受託製造市場の収益規模、タイプ別（2019年～2024年）
8.4 アジア太平洋における抗体薬物複合体受託製造市場の収益規模、用途別（2019年～2024年）
9 ヨーロッパ
9.1 ヨーロッパにおける抗体薬物複合体受託製造市場規模の前年比成長率、2019年〜2030年
9.2 ヨーロッパにおける抗体薬物複合体受託製造市場のファクト・数値、 国別（2019年〜2030年）
9.3 ヨーロッパにおける抗体薬物複合体受託製造市場の収益規模、タイプ別（2019年～2024年）
9.4 ヨーロッパにおける抗体薬物複合体受託製造市場の収益規模、用途別（2019年～2024年）
10 ラテンアメリカ
10.1 ラテンアメリカにおける抗体薬物複合体受託製造市場規模の前年比成長率、2019年〜2030年
10.2 ラテンアメリカにおける抗体薬物複合体受託製造市場のファクト・数値、 国別（2019年〜2030年）
10.3 ラテンアメリカにおける抗体薬物複合体受託製造市場の収益規模、タイプ別（2019年～2024年）
10.4 ラテンアメリカにおける抗体薬物複合体受託製造市場の収益規模、用途別（2019年～2024年）
11 中東・アフリカ
11.1 中東・アフリカにおける抗体薬物複合体受託製造市場規模の前年比成長率、2019年〜2030年
11.2 中東・アフリカにおける抗体薬物複合体受託製造市場のファクト・数値、 国別（2019年〜2030年）
11.3 中東・アフリカにおける抗体薬物複合体受託製造市場の収益規模、タイプ別（2019年～2024年）
11.4 中東・アフリカにおける抗体薬物複合体受託製造市場の収益規模、用途別（2019年～2024年）
12 サプライチェーンと販売チャネル分析
12.1 抗体薬物複合体受託製造サプライチェーン分析
12.2 抗体薬物複合体受託製造の主要原材料と上流サプライヤー
12.3 抗体薬物複合体受託製造の顧客分析
12.4 抗体薬物複合体受託製造の販売チャネルと販売モデルの分析
12.4.1 抗体薬物複合体受託製造の流通チャネル分析： 間接販売 VS 直接販売
12.4.2 抗体薬物複合体受託製造の流通チャネル分析： オンライン販売 VS オフライン販売
12.4.3 抗体薬物複合体受託製造の流通業者
13 市場ダイナミクス
13.1 抗体薬物複合体受託製造業界トレンド
13.2 抗体薬物複合体受託製造市場のドライバー
13.3 抗体薬物複合体受託製造市場の課題
13.4 抗体薬物複合体受託製造市場の抑制要因
14 調査の結果・結論
15 付録
15.1 調査手法
15.1.1 調査手法 / 調査アプローチ
15.1.2 データソース
15.2 執筆者の詳細
15.3 免責事項
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
The global market for Antibody Drug Conjugates Contract Manufacturing was estimated to be worth US$ 2827.3 million in 2023 and is forecast to a readjusted size of US$ 9332.5 million by 2030 with a CAGR of 18.9% during the forecast period 2024-2030.
Key global companies of Antibody Drug Conjugates Contract Manufacturing (ADC) include Lonza, Merck, Recipharm, Thermo Fisher, AbbVie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions and Curia. The top three players are Lonza, Merck and Recipharm, which together account for about 50% of the global market share. The largest player is Lonza Group. From the production side, the global players are mainly concentrated in North America and Europe. North America accounts for about 35% of the global market share. In terms of type, IgG1 dominates the global antibody drug conjugate contract manufacturing market. In terms of application, solid tumor applications account for more than half of the market.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Antibody Drug Conjugates Contract Manufacturing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Antibody Drug Conjugates Contract Manufacturing.
The Antibody Drug Conjugates Contract Manufacturing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antibody Drug Conjugates Contract Manufacturing market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody Drug Conjugates Contract Manufacturing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Lonza Group
Merck KGaA
Recipharm
Thermo Fisher Scientific
Abbvie
Piramal Pharma Solutions
Catalent
Sterling Pharma Solutions
Curia
Novasep
Ajinomoto Bio-Pharma Services
BSP Pharmaceuticals
Cerbios-Pharma
Goodwin Biotechnology
Segment by Type
IgG1
IgG4
Segment by Application
Solid Tumors
Hematological Malignancies
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Antibody Drug Conjugates Contract Manufacturing in global and regional level.
Chapter 3: Detailed analysis of Antibody Drug Conjugates Contract Manufacturing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antibody Drug Conjugates Contract Manufacturing revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
Table of Contents
1 Study Coverage
1.1 Antibody Drug Conjugates Contract Manufacturing Product Introduction
1.2 Market by Type
1.2.1 Global Antibody Drug Conjugates Contract Manufacturing Market Size Growth Rate by Type (2019 VS 2023 VS 2030)
1.2.2 IgG1
1.2.3 IgG4
1.3 Market by Application
1.3.1 Global Antibody Drug Conjugates Contract Manufacturing Market Size Growth Rate by Application (2019 VS 2023 VS 2030)
1.3.2 Solid Tumors
1.3.3 Hematological Malignancies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Antibody Drug Conjugates Contract Manufacturing Market Size Estimates and Forecasts
2.2 Antibody Drug Conjugates Contract Manufacturing Market Size by Region: 2023 Versus 2030
2.2.1 Global Antibody Drug Conjugates Contract Manufacturing Revenue by Region: 2019-2024
2.2.2 Global Antibody Drug Conjugates Contract Manufacturing Revenue Forecast by Region (2025-2030)
2.2.3 Global Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Region (2019-2030)
3 Global Antibody Drug Conjugates Contract Manufacturing by Company
3.1 Global Antibody Drug Conjugates Contract Manufacturing Revenue by Company (2019-2024)
3.2 Global Antibody Drug Conjugates Contract Manufacturing Revenue Share by Company (2019-2024)
3.3 Competitive Landscape
3.3.1 Key Antibody Drug Conjugates Contract Manufacturing Companies around the World: Ranking by Revenue
3.3.2 Global Antibody Drug Conjugates Contract Manufacturing Market Concentration Ratio (CR5 and HHI) & (2019-2024)
3.3.3 Global Antibody Drug Conjugates Contract Manufacturing Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.4 Global Antibody Drug Conjugates Contract Manufacturing Companies Headquarters & Product Type
3.4.1 Antibody Drug Conjugates Contract Manufacturing Companies Headquarters
3.4.2 Global Antibody Drug Conjugates Contract Manufacturing Companies Product & Service
3.4.3 Date of International Companies Enter into Antibody Drug Conjugates Contract Manufacturing Market
3.5 Global Antibody Drug Conjugates Contract Manufacturing Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Lonza Group
4.1.1 Lonza Group Company Information
4.1.2 Lonza Group Description, Business Overview
4.1.3 Lonza Group Antibody Drug Conjugates Contract Manufacturing Products Offered
4.1.4 Lonza Group Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.1.5 Lonza Group Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.1.6 Lonza Group Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.1.7 Lonza Group Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.1.8 Lonza Group Recent Developments
4.2 Merck KGaA
4.2.1 Merck KGaA Company Information
4.2.2 Merck KGaA Description, Business Overview
4.2.3 Merck KGaA Antibody Drug Conjugates Contract Manufacturing Products Offered
4.2.4 Merck KGaA Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.2.5 Merck KGaA Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.2.6 Merck KGaA Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.2.7 Merck KGaA Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.2.8 Merck KGaA Recent Developments
4.3 Recipharm
4.3.1 Recipharm Company Information
4.3.2 Recipharm Description, Business Overview
4.3.3 Recipharm Antibody Drug Conjugates Contract Manufacturing Products Offered
4.3.4 Recipharm Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.3.5 Recipharm Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.3.6 Recipharm Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.3.7 Recipharm Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.3.8 Recipharm Recent Developments
4.4 Thermo Fisher Scientific
4.4.1 Thermo Fisher Scientific Company Information
4.4.2 Thermo Fisher Scientific Description, Business Overview
4.4.3 Thermo Fisher Scientific Antibody Drug Conjugates Contract Manufacturing Products Offered
4.4.4 Thermo Fisher Scientific Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.4.5 Thermo Fisher Scientific Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.4.6 Thermo Fisher Scientific Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.4.7 Thermo Fisher Scientific Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.4.8 Thermo Fisher Scientific Recent Developments
4.5 Abbvie
4.5.1 Abbvie Company Information
4.5.2 Abbvie Description, Business Overview
4.5.3 Abbvie Antibody Drug Conjugates Contract Manufacturing Products Offered
4.5.4 Abbvie Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.5.5 Abbvie Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.5.6 Abbvie Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.5.7 Abbvie Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.5.8 Abbvie Recent Developments
4.6 Piramal Pharma Solutions
4.6.1 Piramal Pharma Solutions Company Information
4.6.2 Piramal Pharma Solutions Description, Business Overview
4.6.3 Piramal Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Products Offered
4.6.4 Piramal Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.6.5 Piramal Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.6.6 Piramal Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.6.7 Piramal Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.6.8 Piramal Pharma Solutions Recent Development
4.7 Catalent
4.7.1 Catalent Company Information
4.7.2 Catalent Description, Business Overview
4.7.3 Catalent Antibody Drug Conjugates Contract Manufacturing Products Offered
4.7.4 Catalent Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.7.5 Catalent Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.7.6 Catalent Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.7.7 Catalent Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.7.8 Catalent Recent Development
4.8 Sterling Pharma Solutions
4.8.1 Sterling Pharma Solutions Company Information
4.8.2 Sterling Pharma Solutions Description, Business Overview
4.8.3 Sterling Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Products Offered
4.8.4 Sterling Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.8.5 Sterling Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.8.6 Sterling Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.8.7 Sterling Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.8.8 Sterling Pharma Solutions Recent Development
4.9 Curia
4.9.1 Curia Company Information
4.9.2 Curia Description, Business Overview
4.9.3 Curia Antibody Drug Conjugates Contract Manufacturing Products Offered
4.9.4 Curia Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.9.5 Curia Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.9.6 Curia Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.9.7 Curia Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.9.8 Curia Recent Development
4.10 Novasep
4.10.1 Novasep Company Information
4.10.2 Novasep Description, Business Overview
4.10.3 Novasep Antibody Drug Conjugates Contract Manufacturing Products Offered
4.10.4 Novasep Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.10.5 Novasep Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.10.6 Novasep Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.10.7 Novasep Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.10.8 Novasep Recent Development
4.11 Ajinomoto Bio-Pharma Services
4.11.1 Ajinomoto Bio-Pharma Services Company Information
4.11.2 Ajinomoto Bio-Pharma Services Description, Business Overview
4.11.3 Ajinomoto Bio-Pharma Services Antibody Drug Conjugates Contract Manufacturing Products Offered
4.11.4 Ajinomoto Bio-Pharma Services Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.11.5 Ajinomoto Bio-Pharma Services Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.11.6 Ajinomoto Bio-Pharma Services Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.11.7 Ajinomoto Bio-Pharma Services Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.11.8 Ajinomoto Bio-Pharma Services Recent Development
4.12 BSP Pharmaceuticals
4.12.1 BSP Pharmaceuticals Company Information
4.12.2 BSP Pharmaceuticals Description, Business Overview
4.12.3 BSP Pharmaceuticals Antibody Drug Conjugates Contract Manufacturing Products Offered
4.12.4 BSP Pharmaceuticals Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.12.5 BSP Pharmaceuticals Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.12.6 BSP Pharmaceuticals Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.12.7 BSP Pharmaceuticals Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.12.8 BSP Pharmaceuticals Recent Development
4.13 Cerbios-Pharma
4.13.1 Cerbios-Pharma Company Information
4.13.2 Cerbios-Pharma Description, Business Overview
4.13.3 Cerbios-Pharma Antibody Drug Conjugates Contract Manufacturing Products Offered
4.13.4 Cerbios-Pharma Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.13.5 Cerbios-Pharma Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.13.6 Cerbios-Pharma Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.13.7 Cerbios-Pharma Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.13.8 Cerbios-Pharma Recent Development
4.14 Goodwin Biotechnology
4.14.1 Goodwin Biotechnology Company Information
4.14.2 Goodwin Biotechnology Description, Business Overview
4.14.3 Goodwin Biotechnology Antibody Drug Conjugates Contract Manufacturing Products Offered
4.14.4 Goodwin Biotechnology Antibody Drug Conjugates Contract Manufacturing Revenue and Gross Margin (2019-2024)
4.14.5 Goodwin Biotechnology Antibody Drug Conjugates Contract Manufacturing Revenue by Product in 2023
4.14.6 Goodwin Biotechnology Antibody Drug Conjugates Contract Manufacturing Revenue by Application in 2023
4.14.7 Goodwin Biotechnology Antibody Drug Conjugates Contract Manufacturing Revenue by Geographic Area in 2023
4.14.8 Goodwin Biotechnology Recent Development
5 Breakdown Data by Type
5.1 Global Antibody Drug Conjugates Contract Manufacturing Revenue by Type (2019-2024)
5.2 Global Antibody Drug Conjugates Contract Manufacturing Revenue Forecast by Type (2025-2030)
5.3 Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Type (2019-2030)
6 Breakdown Data by Application
6.1 Global Antibody Drug Conjugates Contract Manufacturing Revenue by Application (2019-2024)
6.2 Global Antibody Drug Conjugates Contract Manufacturing Revenue Forecast by Application (2025-2030)
6.3 Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Application (2019-2030)
7 North America
7.1 North America Antibody Drug Conjugates Contract Manufacturing Market Size YoY Growth 2019-2030
7.2 North America Antibody Drug Conjugates Contract Manufacturing Market Facts & Figures by Country (2019-2030)
7.3 North America Antibody Drug Conjugates Contract Manufacturing Revenue by Type (2019-2024)
7.4 North America Antibody Drug Conjugates Contract Manufacturing Revenue by Application (2019-2024)
8 Asia-Pacific
8.1 Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Market Size YoY Growth 2019-2030
8.2 Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Market Facts & Figures by Region (2019-2030)
8.3 Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Revenue by Type (2019-2024)
8.4 Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Revenue by Application (2019-2024)
9 Europe
9.1 Europe Antibody Drug Conjugates Contract Manufacturing Market Size YoY Growth 2019-2030
9.2 Europe Antibody Drug Conjugates Contract Manufacturing Market Facts & Figures by Country (2019-2030)
9.3 Europe Antibody Drug Conjugates Contract Manufacturing Revenue by Type (2019-2024)
9.4 Europe Antibody Drug Conjugates Contract Manufacturing Revenue by Application (2019-2024)
10 Latin America
10.1 Latin America Antibody Drug Conjugates Contract Manufacturing Market Size YoY Growth 2019-2030
10.2 Latin America Antibody Drug Conjugates Contract Manufacturing Market Facts & Figures by Country (2019-2030)
10.3 Latin America Antibody Drug Conjugates Contract Manufacturing Revenue by Type (2019-2024)
10.4 Latin America Antibody Drug Conjugates Contract Manufacturing Revenue by Application (2019-2024)
11 Middle East and Africa
11.1 Middle East and Africa Antibody Drug Conjugates Contract Manufacturing Market Size YoY Growth 2019-2030
11.2 Middle East and Africa Antibody Drug Conjugates Contract Manufacturing Market Facts & Figures by Country (2019-2030)
11.3 Middle East and Africa Antibody Drug Conjugates Contract Manufacturing Revenue by Type (2019-2024)
11.4 Middle East and Africa Antibody Drug Conjugates Contract Manufacturing Revenue by Application (2019-2024)
12 Supply Chain and Sales Channel Analysis
12.1 Antibody Drug Conjugates Contract Manufacturing Supply Chain Analysis
12.2 Antibody Drug Conjugates Contract Manufacturing Key Raw Materials and Upstream Suppliers
12.3 Antibody Drug Conjugates Contract Manufacturing Clients Analysis
12.4 Antibody Drug Conjugates Contract Manufacturing Sales Channel and Sales Model Analysis
12.4.1 Antibody Drug Conjugates Contract Manufacturing Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Antibody Drug Conjugates Contract Manufacturing Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Antibody Drug Conjugates Contract Manufacturing Distributors
13 Market Dynamics
13.1 Antibody Drug Conjugates Contract Manufacturing Industry Trends
13.2 Antibody Drug Conjugates Contract Manufacturing Market Drivers
13.3 Antibody Drug Conjugates Contract Manufacturing Market Challenges
13.4 Antibody Drug Conjugates Contract Manufacturing Market Restraints
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables Table 1. Global Antibody Drug Conjugates Contract Manufacturing Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030 Table 2. Major Companies of IgG1 Table 3. Major Companies of IgG4 Table 4. Global Antibody Drug Conjugates Contract Manufacturing Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030 Table 5. Global Antibody Drug Conjugates Contract Manufacturing Market Size by Region (US$ Million): 2023 VS 2030 Table 6. Global Antibody Drug Conjugates Contract Manufacturing Revenue by Region (2019-2024) & (US$ Million) Table 7. Global Antibody Drug Conjugates Contract Manufacturing Revenue Forecast by Region (2025-2030) & (US$ Million) Table 8. Antibody Drug Conjugates Contract Manufacturing Revenue by Company (2019-2024) & (US$ Million) Table 9. Antibody Drug Conjugates Contract Manufacturing Revenue Share by Company (2019-2024) Table 10. Ranking of Global Top Antibody Drug Conjugates Contract Manufacturing Players by Revenue (US$ Million) in 2023 Table 11. Global Antibody Drug Conjugates Contract Manufacturing Companies Market Concentration Ratio (CR5 and HHI) & (2019-2024) Table 12. Global Antibody Drug Conjugates Contract Manufacturing by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Antibody Drug Conjugates Contract Manufacturing as of 2023) Table 13. Global Antibody Drug Conjugates Contract Manufacturing Companies Headquarters Table 14. Global Antibody Drug Conjugates Contract Manufacturing Companies Product & Service Table 15. Date of International Companies Enter into Antibody Drug Conjugates Contract Manufacturing Market Table 16. Global Antibody Drug Conjugates Contract Manufacturing Mergers & Acquisitions, Expansion Plans Table 17. Lonza Group Company Information Table 18. Lonza Group Description and Business Overview Table 19. Lonza Group Antibody Drug Conjugates Contract Manufacturing Product Table 20. Lonza Group Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) and Gross Margin (2019-2024) Table 21. Lonza Group Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Product in 2023 Table 22. Lonza Group Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Application in 2023 Table 23. Lonza Group Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Geographic Area in 2023 Table 24. Lonza Group Recent Development Table 25. Merck KGaA Company Information Table 26. Merck KGaA Description and Business Overview Table 27. Merck KGaA Antibody Drug Conjugates Contract Manufacturing Product Table 28. Merck KGaA Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) and Gross Margin (2019-2024) Table 29. Merck KGaA Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Product in 2023 Table 30. Merck KGaA Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Application in 2023 Table 31. Merck KGaA Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Geographic Area in 2023 Table 32. Merck KGaA Recent Development Table 33. Recipharm Company Information Table 34. Recipharm Description and Business Overview Table 35. Recipharm Antibody Drug Conjugates Contract Manufacturing Product Table 36. Recipharm Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) and Gross Margin (2019-2024) Table 37. Recipharm Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Product in 2023 Table 38. Recipharm Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Application in 2023 Table 39. Recipharm Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Geographic Area in 2023 Table 40. Recipharm Recent Development Table 41. Thermo Fisher Scientific Company Information Table 42. Thermo Fisher Scientific Description and Business Overview Table 43. Thermo Fisher Scientific Antibody Drug Conjugates Contract Manufacturing Product Table 44. Thermo Fisher Scientific Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) and Gross Margin (2019-2024) Table 45. Thermo Fisher Scientific Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Product in 2023 Table 46. Thermo Fisher Scientific Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Application in 2023 Table 47. Thermo Fisher Scientific Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Geographic Area in 2023 Table 48. Thermo Fisher Scientific Recent Development Table 49. Abbvie Company Information Table 50. Abbvie Description and Business Overview Table 51. Abbvie Antibody Drug Conjugates Contract Manufacturing Product Table 52. Abbvie Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) and Gross Margin (2019-2024) Table 53. Abbvie Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Product in 2023 Table 54. Abbvie Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Application in 2023 Table 55. Abbvie Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Geographic Area in 2023 Table 56. Abbvie Recent Development Table 57. Piramal Pharma Solutions Company Information Table 58. Piramal Pharma Solutions Description and Business Overview Table 59. Piramal Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Product Table 60. Piramal Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) and Gross Margin (2019-2024) Table 61. Piramal Pharma Solutions Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Product in 2023 Table 62. Piramal Pharma Solutions Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Application in 2023 Table 63. Piramal Pharma Solutions Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Geographic Area in 2023 Table 64. Piramal Pharma Solutions Recent Development Table 65. Catalent Company Information Table 66. Catalent Description and Business Overview Table 67. Catalent Antibody Drug Conjugates Contract Manufacturing Product Table 68. Catalent Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) and Gross Margin (2019-2024) Table 69. Catalent Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Product in 2023 Table 70. Catalent Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Application in 2023 Table 71. Catalent Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Geographic Area in 2023 Table 72. Catalent Recent Development Table 73. Sterling Pharma Solutions Company Information Table 74. Sterling Pharma Solutions Description and Business Overview Table 75. Sterling Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Product Table 76. Sterling Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) and Gross Margin (2019-2024) Table 77. Sterling Pharma Solutions Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Product in 2023 Table 78. Sterling Pharma Solutions Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Application in 2023 Table 79. Sterling Pharma Solutions Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Geographic Area in 2023 Table 80. Sterling Pharma Solutions Recent Development Table 81. Curia Company Information Table 82. Curia Description and Business Overview Table 83. Curia Antibody Drug Conjugates Contract Manufacturing Product Table 84. Curia Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) and Gross Margin (2019-2024) Table 85. Curia Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Product in 2023 Table 86. Curia Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Application in 2023 Table 87. Curia Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Geographic Area in 2023 Table 88. Curia Recent Development Table 89. Novasep Company Information Table 90. Novasep Description and Business Overview Table 91. Novasep Antibody Drug Conjugates Contract Manufacturing Product Table 92. Novasep Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) and Gross Margin (2019-2024) Table 93. Novasep Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Product in 2023 Table 94. Novasep Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Application in 2023 Table 95. Novasep Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Geographic Area in 2023 Table 96. Novasep Recent Development Table 97. Ajinomoto Bio-Pharma Services Company Information Table 98. Ajinomoto Bio-Pharma Services Description and Business Overview Table 99. Ajinomoto Bio-Pharma Services Antibody Drug Conjugates Contract Manufacturing Product Table 100. Ajinomoto Bio-Pharma Services Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) and Gross Margin (2019-2024) Table 101. Ajinomoto Bio-Pharma Services Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Product in 2023 Table 102. Ajinomoto Bio-Pharma Services Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Application in 2023 Table 103. Ajinomoto Bio-Pharma Services Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Geographic Area in 2023 Table 104. Ajinomoto Bio-Pharma Services Recent Development Table 105. BSP Pharmaceuticals Company Information Table 106. BSP Pharmaceuticals Description and Business Overview Table 107. BSP Pharmaceuticals Antibody Drug Conjugates Contract Manufacturing Product Table 108. BSP Pharmaceuticals Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) and Gross Margin (2019-2024) Table 109. BSP Pharmaceuticals Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Product in 2023 Table 110. BSP Pharmaceuticals Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Application in 2023 Table 111. BSP Pharmaceuticals Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Geographic Area in 2023 Table 112. BSP Pharmaceuticals Recent Development Table 113. Cerbios-Pharma Company Information Table 114. Cerbios-Pharma Description and Business Overview Table 115. Cerbios-Pharma Antibody Drug Conjugates Contract Manufacturing Product Table 116. Cerbios-Pharma Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) and Gross Margin (2019-2024) Table 117. Cerbios-Pharma Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Product in 2023 Table 118. Cerbios-Pharma Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Application in 2023 Table 119. Cerbios-Pharma Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Geographic Area in 2023 Table 120. Cerbios-Pharma Recent Development Table 121. Goodwin Biotechnology Company Information Table 122. Goodwin Biotechnology Description and Business Overview Table 123. Goodwin Biotechnology Antibody Drug Conjugates Contract Manufacturing Product Table 124. Goodwin Biotechnology Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) and Gross Margin (2019-2024) Table 125. Goodwin Biotechnology Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Product in 2023 Table 126. Goodwin Biotechnology Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Application in 2023 Table 127. Goodwin Biotechnology Revenue Proportion of Antibody Drug Conjugates Contract Manufacturing by Geographic Area in 2023 Table 128. Goodwin Biotechnology Recent Development Table 129. Global Antibody Drug Conjugates Contract Manufacturing Revenue by Type (2019-2024) & (US$ Million) Table 130. Global Antibody Drug Conjugates Contract Manufacturing Revenue Forecast by Type (2025-2030) & (US$ Million) Table 131. Global Antibody Drug Conjugates Contract Manufacturing Revenue by Application (2019-2024) & (US$ Million) Table 132. Global Antibody Drug Conjugates Contract Manufacturing Revenue Forecast by Application (2025-2030) & (US$ Million) Table 133. North America Antibody Drug Conjugates Contract Manufacturing Revenue by Country (2019-2024) & (US$ Million) Table 134. North America Antibody Drug Conjugates Contract Manufacturing Revenue by Country (2025-2030) & (US$ Million) Table 135. North America Antibody Drug Conjugates Contract Manufacturing Revenue by Type (2019-2024) & (US$ Million) Table 136. North America Antibody Drug Conjugates Contract Manufacturing Revenue by Application (2019-2024) & (US$ Million) Table 137. Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Revenue by Region (2019-2030) & (US$ Million) Table 138. Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Revenue by Region (2025-2030) & (US$ Million) Table 139. Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Revenue by Type (2019-2024) & (US$ Million) Table 140. Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Revenue by Application (2019-2024) & (US$ Million) Table 141. Europe Antibody Drug Conjugates Contract Manufacturing Revenue by Country (2019-2024) & (US$ Million) Table 142. Europe Antibody Drug Conjugates Contract Manufacturing Revenue by Country (2025-2030) & (US$ Million) Table 143. Europe Antibody Drug Conjugates Contract Manufacturing Revenue by Type (2019-2024) & (US$ Million) Table 144. Europe Antibody Drug Conjugates Contract Manufacturing Revenue by Application (2019-2024) & (US$ Million) Table 145. Latin America Antibody Drug Conjugates Contract Manufacturing Revenue by Country (2019-2024) & (US$ Million) Table 146. Latin America Antibody Drug Conjugates Contract Manufacturing Revenue by Country (2025-2030) & (US$ Million) Table 147. Latin America Antibody Drug Conjugates Contract Manufacturing Revenue by Type (2019-2024) & (US$ Million) Table 148. Latin America Antibody Drug Conjugates Contract Manufacturing Revenue by Application (2019-2024) & (US$ Million) Table 149. Middle East and Africa Antibody Drug Conjugates Contract Manufacturing Revenue by Country (2019-2024) & (US$ Million) Table 150. Middle East and Africa Antibody Drug Conjugates Contract Manufacturing Revenue by Country (2025-2030) & (US$ Million) Table 151. Middle East and Africa Antibody Drug Conjugates Contract Manufacturing Revenue by Type (2019-2024) & (US$ Million) Table 152. Middle East and Africa Antibody Drug Conjugates Contract Manufacturing Revenue by Application (2019-2024) & (US$ Million) Table 153. Antibody Drug Conjugates Contract Manufacturing Key Raw Materials, Industry Status and Trend Table 154. Antibody Drug Conjugates Contract Manufacturing Key Raw Materials and Upstream Suppliers Table 155. Antibody Drug Conjugates Contract Manufacturing Clients Status and Trend Table 156. Antibody Drug Conjugates Contract Manufacturing Typical Clients Table 157. Antibody Drug Conjugates Contract Manufacturing Distributors Table 158. Antibody Drug Conjugates Contract Manufacturing Market Trends Table 159. Antibody Drug Conjugates Contract Manufacturing Market Drivers Table 160. Antibody Drug Conjugates Contract Manufacturing Market Challenges Table 161. Antibody Drug Conjugates Contract Manufacturing Market Restraints Table 162. Research Programs/Design for This Report Table 163. Key Data Information from Secondary Sources Table 164. Key Data Information from Primary Sources List of Figures Figure 1. Antibody Drug Conjugates Contract Manufacturing Product Picture Figure 2. Global Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Type in 2023 & 2030 Figure 3. IgG1 Product Picture Figure 4. IgG4 Product Picture Figure 5. Global Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Application in 2023 & 2030 Figure 6. Solid Tumors Figure 7. Hematological Malignancies Figure 8. Antibody Drug Conjugates Contract Manufacturing Report Years Considered Figure 9. Global Antibody Drug Conjugates Contract Manufacturing Revenue, (US$ Million), 2019 VS 2023 VS 2030 Figure 10. Global Antibody Drug Conjugates Contract Manufacturing Market Size 2019-2030 (US$ Million) Figure 11. Global Antibody Drug Conjugates Contract Manufacturing Market Size Market Share by Region: 2023 Versus 2030 Figure 12. Global Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Region (2019-2030) Figure 13. Antibody Drug Conjugates Contract Manufacturing Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023 Figure 14. Global Antibody Drug Conjugates Contract Manufacturing Revenue Market Share Forecast by Type (2019-2030) Figure 15. Global Antibody Drug Conjugates Contract Manufacturing Revenue Market Share Forecast by Application (2019-2030) Figure 16. North America Antibody Drug Conjugates Contract Manufacturing Revenue 2019-2030 (US$ Million) Figure 17. North America Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Type (2019-2024) Figure 18. North America Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Application (2019-2024) Figure 19. Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Revenue 2019-2030 (US$ Million) Figure 20. Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Region (2019-2030) Figure 21. Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Type (2019-2024) Figure 22. Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Application (2019-2024) Figure 23. Europe Antibody Drug Conjugates Contract Manufacturing Revenue Growth Rate 2019-2030 (US$ Million) Figure 24. Europe Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Country (2019-2030) Figure 25. Europe Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Type (2019-2024) Figure 26. Europe Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Application (2019-2024) Figure 27. Latin America Antibody Drug Conjugates Contract Manufacturing Revenue Growth Rate 2019-2030 (US$ Million) Figure 28. Latin America Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Country (2019-2024) Figure 29. Latin America Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Type (2019-2024) Figure 30. Latin America Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Application (2019-2024) Figure 31. Middle East and Africa Antibody Drug Conjugates Contract Manufacturing Revenue Growth Rate 2019-2030 (US$ Million) Figure 32. Middle East and Africa Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Country (2019-2030) Figure 33. Middle East and Africa Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Type (2019-2024) Figure 34. Middle East and Africa Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Application (2019-2024) Figure 35. Antibody Drug Conjugates Contract Manufacturing Supply Chain (Upstream and Downstream Market) Figure 36. Global Production Market Share of Antibody Drug Conjugates Contract Manufacturing Raw Materials by Region in 2023 Figure 37. Antibody Drug Conjugates Contract Manufacturing Distribution Channels Figure 38. Global Antibody Drug Conjugates Contract Manufacturing Percentage 2019-2030: Indirect Sales VS Direct Sales Figure 39. Global Antibody Drug Conjugates Contract Manufacturing Percentage 2019-2030: Online Sales VS Offline Sales Figure 40. Bottom-up and Top-down Approaches for This Report Figure 41. Data Triangulation Figure 42. Key Executives Interviewed Figure 43. Global Antibody Drug Conjugates Contract Manufacturing Percentage 2019-2030: Online Sales VS Offline Sales Figure 44. Bottom-up and Top-down Approaches for This Report Figure 45. Data Triangulation Figure 46. Key Executives Interviewed
